Possibilities of pharmacological correction of pathologies of gepatobiliarny system


Cite item

Full Text

Abstract

Diseases of the hepatobiliary system increase from year to year. Etiopathogenetic factors of liver lesion development are different, but in all cases of hepatopathies, despite a polietiologichnost of lesions, the treatment of a disease in general is referred on improvement of hepatocytes, and rather close pathogenetic therapy is for this purpose applied. Numerous researches reveal the leading role of an oxidative stress and, provoked by it, the perekisny oxidation of lipids of phospholipid membranes of hepatocytes provoked, by it in development of hepatopathies of any etiology. Taking into account a pathogenesis, of hepatopathies treatment of pathologies assumes an integrated approach. A specific place in the treatment of hepatopathies is held by gepatoprotektor - the means, which rise fastness of hepatocytes to the damaging factors. Today, n medical practice a series of gepatoprotektors of animals, plant and animal origin is used. By present time, are developed and studied a series of drugs of a plant origin, among which, the most often used, and well learned, are drugs of the sum of the flavonoids, received from a spotty thistle. Phytocomplexes for the purpose of their use for treatment and prophylaxis of development of the hepatopathies including caused by use of the medicinal preparations prescribed on vital indicators are framed and are investigated. The review of available literature showed, that despite the sufficient range of hepatoprotective drugs, today, the drugs conforming to clinical requirements no. In this regard search of new and modern highly effective medicines for treatment of the lesions of a liver of various etiology taking into account a development pathogenesis and which aren’t rendering undesirable side effects remains a current problem of medical science and practice. The leading direction is search of these means in group of substances with antioxidatic and antigipoksantny activity.

About the authors

E M Musayeva

Азербайджанскиймедицинскийуниверситет

Баку

G A Huseinova

Азербайджанскиймедицинскийуниверситет

Баку

Sh M Polukhova

Азербайджанскиймедицинскийуниверситет

Баку

S V Gasymova

Азербайджанскиймедицинскийуниверситет

Баку

R E Jafarova

Азербайджанскиймедицинскийуниверситет

Email: rjafarova@bk.ru
Баку

References

  1. Близнецова, Г.Н. Роль процессов свободного окисления в механизме гепатопротекторного действия масла из семян амаранта /Г.Н.Близнецова [и др.] // Биомедицина. - 2006. - №2. -С.105-112.
  2. Грек, О.Р. Гепатопротекторное действие водно-спиртового экстракта диспергированной бересты при остром отрав- лении парацетамолом/ О.Р.Грек [и др.] // Journal of Siberian Medical Sciences. - 2014. -№ 5. - С. 22.
  3. Губергриц, Н.Б. Мультипотентный гепатопротектор ларнамин в клинической практике / Н.Б.Губергриц [и др.] //Гастроэн- терология. - 2016. - №1. -С. 39-47.
  4. Джафарова, Р.Э. Сравнительное фармакологическое ис- следование действия сбора «Антидиабет», галеновых пре- паратов листьев шелковицы белой и травы донника лекар- ственного /Р.Э.Джафарова, Г.Ш. Гараев // AMEA-nınXıbırlıri. Biologiyaelmlıriseriyası. - 2013. -Cild 68, №2.- S.125-130.
  5. Зульфугарова, М.Б. Исследование действия экстрактов цвет- ков, листьев и плодов бузины черной на функциональное состояние печени на фоне экспериментальной модели токсического гепатита / М.Б.Зульфугарова, Р.Э.Джафарова, Г.Ч. Джавадова // Вестн. Росс.воен.-мед.акад. - 2017. - № 1 (57). -С. 124-128.
  6. Матвеев, А.В. Использование силимарина при токсических и вирусных поражениях печени /А.В.Матвеев, Е.И. Коняева // Экспериментальная и клиническая гастроэнтер. - 2011. - № 5. -С. 84-90.
  7. Мышкин, В.А. Изучение эффективности оксиметилурацила в качестве гепатозащитного средства / В.А. Мышкин [и др.] // Медицина труда и экология человека. - 2015. - №2. -С.55-60.
  8. Поготова, Г.А. Гепатотропні засоби: органопротекторна дія (огляд літератури) / Г.А. Поготова [та iнш.]//Вісник проблем біології і медицини. - 2015. - Вип. 1 (117).- С. 19-27.
  9. Рахымжан,Г.Ж. Оценка влияния фитопрепарата на биохими- ческие показатели крови при экспериментальном гепатите / Г.Ж.Рахымжан, А.Н.Аралбаева, М.К. Мурзахметова // On line scientific @ educational Bulletin «Health and Education Millennium». - 2016. - Vol. 18,№ 12. - С. 26- 30.
  10. Степанов, Ю.М. Оцiнка ефективностi гепатопротектора Гепа веда у хворих iз патологiєю печiнки / Степанов Ю.М. [та iнш.] // Гастроэнтерология. - 2015. - №2 (56). -С. 29-32.
  11. Ткач, С.М. L-аргинин-L-аспартат как универсальный гепа- топротектор-детоксикант с плейтропными эффектами /С.М.Ткач // Здоровıя України. - 2013. - №3. - С.60-61.
  12. Ahmed-Belkacem, A. Silibinin and related compounds are direct inhibitors of Hepatitis C virus RNA-dependent RNA polymerase / A.Ahmed-Belkacem [et al.] //Gastroenterology. - 2010. - Vol. 138. - P. 1112-1122.
  13. Allain, H. Aminotransferase levels and silymarin in de novo tacrine-treated patients with Alzheimer’s disease /H.Allain [et al.] // Dement. Geriatr. Cogn. Disord. - 1999. - Vol. 10. - P. 181-185.
  14. Axundov, R.A. Фитопрепаратывлечениипатологиипече- ни/R.A.Axundov [et al.] // Saglamlıq. - 2016. -№ 2. - C. 7-12.
  15. Blendis, L. Interferon treatment of HCV: do we need a virological response? / L.Blendis, R.Oren, Z.Halpern // Gastroenterology. - 2002. - Vol. 122. - P. 237-238.
  16. Bunchorntavakul, Ch. Drug Hepatotoxicity: Newer Agents/ Ch.Bunchorntavakul, K.Rajender Reddy // Clinics in Liver Disease. - 2017. - Vol. 21, Issue 1. - P. 115-134.
  17. El-Kamary, S.S.A randomized controlled trial to assess the safety and efficacy of silymarin on symptoms sings and biomarkers of acute hepatitis / S.S.El-Kamary [et al.] // Phytomedicine - 2009. - Vol.16, № 5. - P.391-400.
  18. Eminzade, S. Silymarin protects liver against toxic effects of antituberculosis drugs in experimental animals / S.Eminzade, F.Uraz, F.V. Izzettin // Nutr. Metab. - 2008. - Vol. 5. - P. 18.
  19. Favari, L. Comparative effects of colchicines and silymarin on carbon tetrachloride chronic liver damage in rats / L.Favari, V.Perez-Alvarez // Arch. Med. Res. - 1997. - Vol. 28. - P. 11-17.
  20. Ferenci, P. Silibinin is a potent antiviral agent in patients with chronic hepatitis c not responding to pegylated interferon/ ribavirin therapy / P.Ferenci [et al.] // Gastroenterology. - 2008. - Vol. 135. - P. 1561-1567.
  21. Ho, H. Virtual liver models in pre-surgical planning, intra-surgical navigation and prognosis analysis/ H.Ho,A. Bartlett, P.Hunte // Drug Discovery Today: DiseaseModels. - 2016. -Vol. 22.- P. 51-56.
  22. Ladas, E.J. A randomized, controlled, double-blind, pilot study of milk thistle for the treatment of hepatotoxicity in childhood acute lymphoblastic leukemia /E.J.Ladas [et al.] // Cancer. - 2010. - Vol. 116, № 2. - P. 506-513.
  23. Lirussi, F. Cytoprotection in the nineties: experience with ursodeoxycholic acid and silymarin in chronic liver disease / F.Lirussi, L.Okolicsanyi // Acta Physiol. Hung. - 1992. - Vol. 80, № 1-4. - P. 363-367.
  24. Luyendyk, J.P. Inflammation and Hepatotoxicity/ J.P. Luyendyk [et al.]// Encyclopedia. - 2018. - Vol.2. - P. 324-345.
  25. Magliulo, E. Results of a double blind study on the effect of silymarin in the treatment of acute viral hepatitis, carried out at two medical centres / E.Magliulo, B.Gagliardi,G.P. Fiori // Med. Clin. - 1978. - Vol. 73, № 28-29. - P. 1060-1065.
  26. Mourelle, M. Erythrocyte defects precede the onset of carbon tetrachloride-induced liver cirrhosis: protection by silymarin / M.Mourelle, M.T. Franco // Life Sci. - 1991. - Vol. 48. - P. 1083-1090.
  27. Mourelle, M. Prevention of carbon tetrachloride-induced liver cirrhosis by silymarin / M. Mourelle [et al.] // Fundam. Clin. Pharmacol. - 1989. - Vol. 3. - P. 183-191.
  28. Novik, E.I. Long-enduring primary hepatocyte-based co- cultures improve prediction of hepatotoxicity/ E.I. Novik [et al.] // Toxicology and Applied Pharmacology. - 2017. -Vol. 336. - P.20-30.
  29. Palasciano, G. The effect of silymarin on plasma levels of malondialdehyde in patients receiving longterm treatment with psychotropic drugs / G. Palasciano [et al.] // Curr. Th er. Res. Clin. Exp. - 1994. - Vol. 55. - P. 537-545.
  30. Patel, V. Drug-Induced Steatohepatitis/ V. Patel, A.J. Sanyal // Clinics in LiverDisease.- 2013. - Vol. 17. - Issue 4. -Р.533-546.
  31. Pawlotsky, J.M. HCV inhibition by silibinin, the main component of silymarin, and related flavonoids: insights into its molecular mechanisms / J.M. Pawlotsky // Materials of the 45th Annual Meeting of the European Association for the Study of the Liver «New perspective in the clinical use of silymarin/silibinin»- April 15, 2010. - Vienna, Austria. - P. 9-10.
  32. Payer, B.A. Successful HCV eradication and inhibition of HIV replication by intravenous silibinin in an HIV-HCV coinfected patient /B.A.Payer [et al.] // J. Clin. Virology. - 2010. - Vol.49. - P. 131-133.
  33. Polyak, S.J. Inhibition of T-cell inflammatory cytokines, hepatocyte NF-ıB signaling, and HCV infection by standardized silymarin / S.J. Polyak // Gastroenterology. - 2007. - Vol. 132. - P. 1925-1936.
  34. Popov, Y. Targeting liver fibrosis: strategies for development and validation of antifibrotic therapies / Y.Popov, D. Schuppan // Hepatology. - 2009. - Vol. 50, № 4. - P. 1294-1306.
  35. Ramappa, V. Hepatotoxicity Related to Antituberculosis Drugs: Mechanisms and Management/ V.Ramappa, G.P.Aithal // Journal of Clinical and Experimental Hepatology. - 2013. - Vol.3. - Issue 1. - P. 37-49).
  36. Shehu, A.I. Mechanisms of Drug-Induced Hepatotoxicity/ A.I.Shehu, X.Ma, R. Venkataramanan // Clinics in Liver Disease. - 2017. - Vol. 21. - Issue 1. -P. 35-54.
  37. Shindo, M. Long-term follow-up study of sustained biochemical responders with interferon therapy /M.Shindo [et al.] // Hepatology. - 2001. - Vol. 33, № 5. - P. 1299-1302. 224 2 (62) - 2018 ВЕСТНИК РОССИЙСКОЙ ВОЕННО-МЕДИЦИНСКОЙ АКАДЕМИИ Обзоры
  38. Tasduq, S.A. Biochemical manifestations of antituberculosis drugs induced hepatotoxicity and the effect of silymarin /S.A.Tasduq [et al.] // Hepatol. Res. - 2005. - Vol. 31. - P. 132-135.
  39. Testino, G. Silimarin and S-adenosyl-L methionine (SAME): two promising pharmacological agents in case of cronic alcoholic hepathopathy /G.Testino [et al.] // Minerva Gastroenterol. Dietol. - 2013,Vol.59,№4. -Р.341-356.
  40. Vailati, A. Randomized open study of the dose effect relationship of a short course of IdB 1016 in patients with viral or alcoholic hepatitis /A.Vailati [et al.] // Fitoterapia. - 1993. - Vol. 64, № 3. - P. 219-228.
  41. Valenzuela, A. Silybin dihemisuccinate protects rat erythrocytes against phenylhydrazine-induced lipid peroxidation and hemolysis / A.Valenzuela,R. Guerra, A.Garrido // Planta Med. - 1987. - Vol. 53. - P. 402-405.
  42. Valezuela, A. Inhibitory effect of the flavonoid silymarin on the erythrocyte hemolysis induced by phenylhydrazine / A. Valezuela [et al.] // Biochem. Biophys. Res. Commun. - 1985. - Vol. 126. - P. 712-718.
  43. Wagoner, J. Multiple effects of silymarin on the hepatitis C virus lifecycle / J.Wagoner [et al.]// Hepatology. - 2010. - Vol. 51. - P. 1912-1921.
  44. Waly Raphael, S. Hepato-cellular carcinoma: focus on different aspects of management / S.Waly Raphael, Z.Yangde, C. Yuxiang // ISRN Oncol. - 2012. - Vol. 12. -P. 1-12.

Copyright (c) 2018 Musayeva E.M., Huseinova G.A., Polukhova S.M., Gasymova S.V., Jafarova R.E.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies